Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach

BACKGROUND: Clinical practice guidelines recommend the use of bone-targeting agents for preventing skeletal-related events (SREs) among patients with bone metastases from solid tumors. The anti-RANKL monoclonal antibody denosumab is approved for the prevention of SREs in patients with bone metastase...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacobson, Dionna, Cadieux, Benoit, Higano, Celestia S., Henry, David H., Bachmann, Basia A., Rehn, Marko, Stopeck, Alison T., Saad, Hossam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976128/
https://www.ncbi.nlm.nih.gov/pubmed/35378840
http://dx.doi.org/10.1016/j.jbo.2022.100423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976128/
https://www.ncbi.nlm.nih.gov/pubmed/35378840
http://dx.doi.org/10.1016/j.jbo.2022.100423

Ejemplares similares